ReviewFrontiers in oncology2020
Lobular Breast Cancer: A Review.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Prospective study onBritish journal of cancer · 2026Trial
- Article
- Ascitic Fluid Cytology Provides Diagnostic Clues in a Case of Gastric Metastasis from Invasive Lobular Carcinoma of the Breast.Surgical case reports · 2026Article
- Molecular and Biological Features of Invasive Lobular Carcinoma: Toward New Treatment Strategies.Annals of surgical oncology · 2026Review
- Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie Hospitals.Scientific reports · 2025Article
- Differential prognostic significance of tumor size and node in invasive lobular carcinoma of breast.Breast cancer research : BCR · 2025Article
- Clinicopathological Features of HER2 Expressing Lobular Carcinoma of Breast.World journal of oncology · 2025Article
- Demographic and clinical predictors of treatment outcomes in invasive lobular carcinoma breast cancer: insights from Cox regression analysis.Discover oncology · 2025Article
- Extending catchment area approaches to a community cancer center: a breast cancer hotspot case study.JNCI cancer spectrum · 2025Article
- A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.NPJ breast cancer · 2025Article
- Phytoactive Molecules and Nanodelivery Approaches for Breast Cancer Treatment: Current and Future Perspectives.Current pharmaceutical biotechnology · 2025Review
- Diagnostic dilemma of lobular carcinoma: a mini-review of imaging modalities and the role of artificial intelligence and radiomics.Frontiers in oncology · 2025Review
- The Landscape of Breast Cancer Molecular and Histologic Subtypes in Canada.Current oncology (Toronto, Ont.) · 2024Article
- CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency.Breast cancer research : BCR · 2024Article
- Triple-Negative Pleomorphic Lobular Carcinoma in a BRCA1 Mutation Carrier: A Case of Complete Pathological Response.The American journal of case reports · 2024Article
- Article
- Article
- Personalized circulating tumor DNA response to local radiotherapy in a patient with an early lobular breast cancer: A case report.Oncology letters · 2024Article
- Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.British journal of cancer · 2024Article
- Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland.Current oncology (Toronto, Ont.) · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive lobular carcinoma accounts for 5%-15% of all invasive breast cancers, with a marked increase in incidence rates over the past two decades. Distinctive biological hallmarks of invasive lobular carcinoma include the loss of cell adhesion molecule E-cadherin leading to cells with a discohesive morphology, proliferating into single-file strands and estrogen receptor positivity. These key molecular features can make diagnosis difficult, as invasive lobular carcinoma is challenging to detect both physically and with current standard imaging. Treatment of invasive lobular carcinoma strongly favors endocrine therapy due to low chemosensitivity and lower rates of pathological response as a result. This review will summarize the distinct biological and molecular features of invasive lobular carcinoma, focusing on the diagnostic challenges faced and the subsequent surgical and medical management strategies. Prospective therapeutic options will also be explored, highlighting how furthering our understanding of the unique biology of lobular breast carcinoma is essential in guiding and informing the treatment of patients in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.